Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of JY09 on PK of Metformin, Rosuvastatin, Digoxin and QT Interval in Overweight Subjects
NCT06247748Phase 1Completed
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JY-09 in type 2 diabetes mellitus (T2DM) and Overweight, sponsored by Beijing Dongfang Biotech Co., Ltd. Primary endpoints: Metformin Peak Concentration (Cmax), Area under the Metformin blood concentration-time curve and 4 more. Started Oct 2023; status: completed.
02
Drugs
JY-09
03
Conditions
type 2 diabetes mellitus (T2DM)Overweight
Beyond the preview
Go deeper on NCT06247748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247748.